Protara Therapeutics (TARA) just unveiled an announcement.
Protara Therapeutics, Inc. has announced the resignation of their Chief Medical Officer, Dr. Jathin Bandari, effective April 11, 2024, as he shifts focus to other opportunities and academic pursuits. Although leaving, Dr. Bandari will still offer consulting services to Protara until July 11, 2024. Under the terms of his separation agreement, he will receive a lump sum of his base salary for nine months, part of his annual bonus, and other financial benefits, including vested stock options. In the interim, Dr. Jacqueline Zummo will take charge of the clinical trial teams with Dr. Richard Levy’s guidance, while the company searches for a new CMO.
Find detailed analytics on TARA stock on TipRanks’ Stock Analysis page.
